Endocrine- DM Flashcards

1
Q

How is Insulin released?

What is the structure of insulin?

A
  • Insulin is released as proinsulin, a precursor molecule
  • Insulin is a small protein consisting of a chain of 21 amino acids linked by two disulfide (s-s) bridges to a Beta chain of 30 amino acids
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the MOA of insulin?

A
  • Insulin binds to plasma membrane receptors initiating an intracellular cascade of enzymatic events
    • glucose diffusion into cell
    • glucose storage mode (glycogen synthetase)
    • uptake of amino acids, phosphate, K, and Mg
    • protein syntheisis and inhibition of proteolysis
    • increased fatty acid and triglyceride synthesis; decreased lipolysis
    • regulate DNA/gene expression via insulin regulatory elements
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is normal endogenous insulin physiology?

A
  • Portal circulation receives basal rate of 1 U per hour
  • With meals this rate of insulin secretion increases 5-10x
  • 40U is average daily requirement
  • “units” is a term used to quantify potency
    • i.e. ability to decrease serum BS
  • ANS does influence insulin secretion
    • alpha decreases insulin secretion
    • beta and PSNS increase insulin secretion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Who needs insulin therapy?

A
  • Type 1 diabetics
    • insulin dependent b/c their body produces NO insulin
  • Type 2 diabetics
    • do not always produce enough insulin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the three different ways insulin has been made over time?

A
  • Stage 1: insulin was extracted from the glands of cows and pigs
  • Stage 2: Pig insulin was converted into human insulin by removing the one amino acid that was different and replacing it with human kind
  • Stage 3: Insert human insulin into E.coli and culture the recombinant E.coli to produce insulin. (Humulin)
    • Yeast can also be used (Novolin)
    • recombinant method has also made it possible to have insulins that work faster or slower than regular
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the different types of insulin?

A
  • Ultrarapid acting
    • Lispro (humalog)
    • Aspart (Novolog)
    • Glulisine (apidra)
  • Short acting
    • Regular (humulin R, novolin R)
  • Intermediate acting
    • NPH (humulin N, Novolin N)
  • Long acting
    • Glargine (lantus)- has no peak
    • Detemir (levemir)
    • ultralente
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do the peak effects of the different SQ insulins vary?

(graph)

A
  • short duration, fast acting (lispro)- 1-2 hours
  • short duration , slow acting (regular)- 3-4 hours
  • intermediate duration, slow acting (NPH)- 6-7 hours
  • long duration, slowest acting (glargine)- no peak
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Random insulin considerations:

HOw can insulin be administered?

What are the benefits of all the different options?

Which insulin can you not mix with any others?

A
  • Insulin can be administered parenterally and nasally
    • SQ is most common
  • Benefits of different onsets/durations:
    • rapid- convenient, can inject minutes before a meal
    • mixtures (rapid/NPH)- R covers breakfast, NPH covers lunch; R covers dinner, NPH covers o/n
    • Long acting- mimics basal insulin
  • Do not mix Glargine with any other insulins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the pharmacokinetics of IV regular insulin?

E1/2t

DOA

metabolism

formulation?

A
  • E1/2t- 5-10 minutes
  • DOA- 30-60 minuts
    • longer than you would expect with short 1/2t b/c insulin tightly binds to receptors
  • Metabolized in liver and kidney by proteolytic enzymes
  • Only the U100 formulation should be used
    • there is a U500 formulation that should never be administered IV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Onset, peak, duration, and Use for: (table)

Rapid acting (lispro)

short acting (regular)

intermed (NPH)

Long acting (glargine)

ultralong ancting (dugludec)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are some of the convenient ways to administer insulin?

A

insulin pens

jet injectors

insulin pumps (be sure to disable/remove)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the adverse effects of insulin?

A
  • Injection site rxns
  • lipodystrophy at injection site
  • protamine allergy
  • weight gain
  • HYPOGLYCEMIA
    • diaphoresis, tachycardia, HTN, CNS agitation, sz, coma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What drugs interact with insulin?

A
  • Appose the hypoglycemic effects of insulin:
    • ACTH, glucagon, estrogens
  • Decrease release of insulin and stimulates mobilization of glucose:
    • epinephrine
  • prolongs DOA:
    • tetracycline, chloramphenicol, salicylates
  • Increase hypoglycemic effects
    • MAOIs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pacito a pacito,

suave suavecito…

A

…..Des-pa-cito!!

¡Vamos a una playa en Puerto Rico!!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How much does 1U insulin decrease BS in a pt with type 1 DM?

Type 2 DM?

A
  • Type 1- 1U decreases BS by 40-50 mg/dl
  • Type 2- 1U decreases BS by 30-40 mg/dl
  • **individual sensitivity is highly variable!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the benefits of tight control of BS?

A
  • tight control reduces the risk of chronic complications in type 1 diabetics
  • may affect surgical morbidity and mortality
    • increased wound healing
    • decreased infection
    • decreased osmotic diuresis
    • decreased incidence of diabetic ketoacidosis
17
Q

What are the drawbacks of tight control of BS?

A
  • risk of hypoglycemia
    • can cause permanent neurological damage
    • signs and symptoms are masked by anesthesia
  • tight control is labor intensive
  • requires BS monitoring q30 min
18
Q

How do you treat hyperkalemia with insulin?

A
  • 10 U RegularIV and 25 g of glucose (1 amp of 50% dextrose solution over 5 minutes)
19
Q

How do you treat hypoglycemia?

A
  • Critical to avoid brain damage and death!
  • If conscious, give fast acting oral sugar
  • If under anesthesia/impaired, 25-50 ml of 50% dextrose
20
Q

What are the different types of oral antidiabetic medications?

How do they work?

*bolded answers are the ones that have risk of hypoglycemia

A
  • Sulfonylureas- increase insulin secretion from Beta cells
  • Biguanides- increase insulin sensitivity at target tissue
  • Thiazolidinediones- increase insulin sensitivity at target tissues
  • Alpha-glucosidase inhibitors- slows absorption from the gut
  • Meglitinides- increase insulin secretion from B cells
  • GLP-1 Mimetics/Gliptins (DPP-4 inhibitors)- increase insulin from B cells
21
Q

Sulfonylureas

MOA

A
  • MOA- stimulate release of insulin from pancreatic beta cells
    • binds to ATP sensitive K channels in the cell membrane resulting in depolarization, Ca influc and insulin release
22
Q

What are the Sulfonylureas that we use?

What are each of their DOA?

A
  • second generation- 100x more potent with less SE than first generation
    • glipizide- DOA 12-24 hours
    • Glyburide (Micronase, Diabeta)- DOA 18-24 hours
    • Glimepiride (Amaryl)
  • first generation (don’t use)
    • Tolbutamide (Orinase)- DOA 6-12 hours
    • Chlorpropamide (Diabinese)- DOA 36-72 hours
23
Q

Pharmacokinetics of Sulfonylureas:

PB

metab

What should you use with renal impairment?

SE

How long should it be held pre-op?

A
  • 90-98% PB (albumin)
  • All metabolized hepatically, some have active metabolites; avoid in hepatic disease
  • If renally impaired, use glipizide or tolbutamide- completely metabolized to inactive or weakly active states
  • SE
    • GI- nauesea, fullness, heartburn, cholestasis, appetite stimulant
    • GU- ADH like effect, Na and H2O retention
    • Derm- pruritis, rash
    • Hypoglycemia
  • Hold 24-48 hours pre-op
24
Q

Biguanides

only drug

MOA

excretion

clinical effects

A
  • Metformin (Glucophage)
  • MOA
    • decreases hepatic and renal glucose producition (gluconeogenesis and glycogenolysis)
    • enhances insulin receptor binding
    • increases glucose utilization and decreases insulin resistance
  • Excreted by kidneys
  • Clinical effects:
    • decreases FPG 60 mg/dl
    • additive effect with sulfonylureas
25
Biguanides (Metformin) benefits adverse effects contraindications
* Benefits * no wt gain, even modest wt loss * may increase HDL, decrease LDL and TG * Hypoglycemia rare when used alone * Adverse effects * GI distress- diarrhea/nausea * lactic acidosis * rash * Contraindications * ESRD (CR\>1.4) * hepatic dysfunction * CHF, shock, hypoxic pulmonary disease
26
What are the Thiazolidinediones (TZDs) MOA
* Pioglitazone (Actos) * Rosiglitazone (Avandia) * MOA * **Improves insulin sensitivity/decreases resistance** * especially in skeletal muscle and adipose tissue * Reduces hepatic glucose production * requires the presence of insulin for effect
27
Thiazolidinediones Clinical effect pharmacokinetics other effects
* Clinical effects: * decreases FPG up to 50 mg/dl * decreases Hgb A1c 1-2% * Pharmacokinetics * PO * hepatic metabolism * Other effects- resumption of ovulation in premenopausal women who were experiencing anovulation from insulin resistance
28
Thiazolidinediones Major adverse effects
* Adverse effects: * edema * weight gain * hepatoxicity- monitor LFTs, counsel pts about symptoms of jaundice * BLACK BOX * CHF- can cause or exacerbate * MI
29
What are the Alpha-glucosidase inhibitors? MOA?
* Acarbose (Precose) * Miglitol (Glyset) * MOA * Competitively and reversibly antagonizes enzymes in the intestinal brush border responsible for digesting complex carbs * delays glucose absorption * lowers post-prandial hyperglycemia
30
Alpha-glucosidase inhibitors clinical effect pharmacokinetics adverse effects
* clinical effect * Only decreases FBG 25-30 mg/dl * decreases PPG 60-70 mg/dl (post prandial) * decreases HghA1c 0.7-0.9% * Pharmacokinetics * Taken with first bit of food * not absorbed after oral administaration * excreted in stool * Adverse effects * GI- distension, pain, diarrhea, flatulence * Caution in pts with IBD, UC, obstruction
31
What are the Meglitinides? MOA?
* Repaglinide (prandin) * Nateglinide (Starlix) * MOA * stimulates insulin secretion from the B cells * quick onset and peak effect (1 hour) * short DOA (4 hours) * reduces PPG
32
How are Meglitinides administered? SE?
* Dosing PO * 15-30 minutes before a meal * skip a meal, skip a dose * SE * similar to sulfonylureas * hypoglycemia * GI- N/V/C/D, heartburn * HA
33
How do the GLP-1 Agonists and Mimetics "Gliptins" work?
* Inhibit DPP-4 (dipeptidyl peptidase), an enzyme that inactivates incretin hormones (GLP-1) * Enhances glucose-dependent insulin secretion * reduces glucagon secretion * exhibits other anti-hypoglycemic actions once released from the gut including decreased appetite and slowing gastric emptying
34
What GLP-1 agonist do you especially have to worry about risk of aspiration with?
* Sitagliptan (Januvia) * E1/2t 12 hours * modestly reduces PPG and FPG * SE comparable to placebo
35
What type of drug is Exenatide (Byetta)?
* Injectable (SQ) Synthetic GLP-1 analog that mimics GLP-1 * nearly identical affects as gliptins * adjuct to metformin or sulfonylureas * no wt gain * Adverse effects: * N/V * some pts develop antibody agains the drug * pancreatitis- potentially fatal * renal failure- 1:13,000 (transplant required) * hypersensitivity * delayed gastric emptying
36
What are the Amylin Mimetics?
* Pramlintide SQ- synthetic analog of amylin, a pancreatic hormone released with insulin, that decreases gastric emptying, decreases glucagon secretion, and increases sensation of satiety * Reduces PPG * peakse 20 min after injection, 49 min 1/2 life * metabolized in kidneys * enhances insulin effects * SE- **hypoglycemia**, decreased absorption of drugs (ABX, oral contraceptives 1 hr before or 2 hr after injection)